ID   MES-SA/Dx5
AC   CVCL_2598
SY   MES-SA/Dx-5; MES-SA-Dx5; MES-SA Dx5; MESSA/Dx5; MESSA-DX5; MESSA Dx5; MESSADX5; Dx5
DR   CLO; CLO_0007678
DR   CLO; CLO_0037164
DR   CLDB; cl3449
DR   ArrayExpress; E-MTAB-38
DR   ATCC; CRL-1977
DR   BCRC; 60331
DR   BCRJ; 0403
DR   BioSample; SAMN03470985
DR   BioSample; SAMN03471267
DR   cancercelllines; CVCL_2598
DR   Cell_Model_Passport; SIDM01225
DR   ChEMBL-Cells; CHEMBL3308373
DR   ChEMBL-Targets; CHEMBL613827
DR   ECACC; 95051031
DR   GEO; GSM827348
DR   GEO; GSM1676305
DR   GEO; GSM1701640
DR   IGRhCellID; MESSADX5
DR   LINCS_LDP; LCL-1510
DR   Progenetix; CVCL_2598
DR   PubChem_Cell_line; CVCL_2598
DR   Wikidata; Q54905250
RX   PubMed=4028002;
RX   PubMed=15816562;
RX   PubMed=20215515;
RX   PubMed=22889595;
RX   PubMed=25877200;
RX   PubMed=26351324;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 30 hours (ECACC=95051031).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gly1610Trpfs*38 (c.4826dupC) (p.S1609fs) (c.4825_4826insC); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Thr1690Asnfs*8 (c.5068dupA) (c.5067_5068insA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His272Thrfs*4 (c.813delT) (p.Phe271fs) (c.811delT); ClinVar=VCV000428208; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Misspelling: MES-AS/Dx5; BCRJ=0403.
CC   Misspelling: MES-SA/DxS; ChEMBL-Targets=CHEMBL613827; ChEMBL-Cells=CHEMBL3308373.
CC   Discontinued: ATCC; CRL-1977; true.
CC   Derived from site: In situ; Uterus; UBERON=UBERON_0000995.
ST   Source(s): ATCC=CRL-1977; Technion Genomics Center BCF; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D10S1248: 14,15
ST   D12S391: 17,25
ST   D13S317: 13
ST   D16S539: 11,12
ST   D18S51: 15
ST   D19S433: 14.2,15
ST   D1S1656: 14,17.3
ST   D21S11: 29,30.2
ST   D22S1045: 16
ST   D2S1338: 17
ST   D2S441: 10,14
ST   D3S1358: 14,17
ST   D5S818: 13
ST   D7S820: 7,11 (ATCC=CRL-1977)
ST   D7S820: 11 (Technion Genomics Center BCF; PubMed=25877200)
ST   D8S1179: 14,15
ST   FGA: 20,25
ST   Penta D: 13,15
ST   Penta E: 7,10
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C6339; Uterine corpus sarcoma
DI   ORDO; Orphanet_213620; Sarcoma of the corpus uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1404 ! MES-SA
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 31
//
RX   PubMed=4028002;
RA   Harker W.G., Sikic B.I.;
RT   "Multidrug (pleiotropic) resistance in doxorubicin-selected variants
RT   of the human sarcoma cell line MES-SA.";
RL   Cancer Res. 45:4091-4096(1985).
//
RX   PubMed=15816562;
RA   Wesolowska O., Paprocka M., Kozlak J., Motohashi N., Dus D.,
RA   Michalak K.;
RT   "Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for
RT   multidrug resistance modulators screening.";
RL   Anticancer Res. 25:383-389(2005).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22889595; DOI=10.1016/j.jprot.2012.07.047;
RA   Lin S.-T., Chou H.-C., Chang S.-J., Chen Y.-W., Lyu P.-C., Wang W.-C.,
RA   Chang M.D.-T., Chan H.-L.;
RT   "Proteomic analysis of proteins responsible for the development of
RT   doxorubicin resistance in human uterine cancer cells.";
RL   J. Proteomics 75:5822-5847(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//